Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

77265

	registered interest
	date	10/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Lyme Disease
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government whether, in December 2011, the Clinical Pathology Accreditation Service was made aware of modifications by the Health Protection Agency’s Lyme Borreliosis Unit to the Trinity Biotech immunoblot kit to be used for testing human cerebrospinal fluid.
	tabling member printed	The Countess of Mar
	uin	HL999
	answer	answer is ministerial correction date of answer 24/07/2014 answer text <p>The former Health Protection Agency's Lyme Borreliosis Unit (HPA LBU) was accredited by Clinical Pathology Accreditation who had access to, and was able to review, all the standard operating procedures of the unit.</p><p> </p><p>The Trinity Biotech Lyme Western Blot is a qualitative in vitro assay for the detection of Immunoglobulin (IgG or IgM) antibodies in human samples against specific antigens/proteins of <em>Borrelia afzelii, Borrelia garinii and Borrelia burgdorferi</em>. The Trinity Biotech Lyme Western Blot is intended as a confirmatory assay for use in testing human samples which have been previously found to be positive or equivocal using an Enzyme Immunoassay and Immunofluroescent Assay or other appropriate screening method. Positive second-tier results are supportive evidence of infection with <em>B. burgdorferi</em>. The diagnosis of Lyme disease should be made based on history and symptoms (such as erythema migrans), and other laboratory data, in addition to the presence of antibodies to <em>B. burgdorferi</em>. The Trinity Biotech blot has been in use since 2007 by the former HPA’s LBU for testing cerebrospinal fluid (CSF) and proved very reliable. This technique has also been in use widely across Europe during this period as a diagnostic test using CSF as a sample to support the diagnosis of neuroborreliosis.</p> answering member printed Earl Howe question first answered 24/07/2014 12:32:59 answering member 2000 label Biography information for Earl Howe
	tabling member	1861 label Biography information for The Countess of Mar

77264

	registered interest
	date	10/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Lyme Disease
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government when the testing of the cerebrospinal fluid of patients suspected of having Lyme disease using the Trinity Biotech kit at the Health Protection Agency’s Lyme Borreliosis Unit began; how many patients' samples were tested in that way; and how many patients were recorded as being positive over that period of time.
	tabling member printed	The Countess of Mar
	uin	HL998
	answer	answer is ministerial correction date of answer 24/07/2014 answer text <p>The Trinity Biotech blot has been in use since 2007 by the former Health Protection Agency's Lyme Borreliosis Unit for testing cerebrospinal fluid (CSF) and proved very reliable. It has also been used in this way by other laboratories in Europe. However, CSF antibodies will not be present if there is no evidence of any other antibodies in the serum. Data is not collected centrally on specific samples from patients as the final diagnosis is made by the clinician on the basis of the test results and the clinical presentation.</p> answering member printed Earl Howe question first answered 24/07/2014 12:31:17 answering member 2000 label Biography information for Earl Howe
	tabling member	1861 label Biography information for The Countess of Mar

386888

	registered interest
	date	01/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Amyloidosis
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government which of the four phase 2 or 3 clinical trials for systemic amyloidosis approved since 2004 are still ongoing; and whether any of the trials have produced sufficient positive outcomes to encourage commercial development.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL997
	answer	answer is ministerial correction date of answer 14/07/2015 answer text <p>There are four trials for systemic amyloidosis that are designated as ‘ongoing’ in the United Kingdom. These are being conducted by two commercial sponsors, Millennium Pharmaceuticals Inc and A.T. Development Switzerland Sarl (two studies), and one non-commercial sponsor, European Myeloma Network.</p><p> </p><p> </p><p> </p><p>Clinical trial sponsors are required to publish a summary of their trial results to the EU Clinical Trials Register within one year of their trial completing. At that point, these results will become publically available on the EU Clinical Trials Register</p><p> </p><p> </p><p> </p><p>The Department of Health, which funds the National Institute for Health Research (NIHR), is a member of the National Cancer Research Institute (NCRI). NCRI Clinical Studies Groups (CSGs) bring together clinicians, scientists, statisticians and lay representatives to coordinate development of a strategic portfolio of trials within their field. All CSGs interact with clinical research networks, funders (including NIHR) and researchers to develop studies aimed at improving outcomes for patients. The Haematological Oncology CSG has a Myeloma Subgroup and its 2013-14 annual report that includes an assessment of progress in these areas is attached and available on the NCRI website at:</p><p> </p><p><a href="http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf" target="_blank">http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf</a>.</p><p> </p><p> </p><p> </p><p>We cannot comment on commercial considerations. When the results are known, the commercial potential of these trial’s products will be a matter for the respective trial sponsors.</p><p> </p> answering member printed Lord Prior of Brampton grouped question UIN HL995 HL996 question first answered 14/07/2015 15:34:29 answering member 127 label Biography information for Lord Prior of Brampton attachment 1 file name NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf title 2013-14 Annual Report
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

386887

	registered interest
	date	01/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Amyloidosis
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government whether there are currently any trials for systemic amyloidosis in humans being conducted by the National Institute of Health Research charities or the commercial sector.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL996
	answer	answer is ministerial correction date of answer 14/07/2015 answer text <p>There are four trials for systemic amyloidosis that are designated as ‘ongoing’ in the United Kingdom. These are being conducted by two commercial sponsors, Millennium Pharmaceuticals Inc and A.T. Development Switzerland Sarl (two studies), and one non-commercial sponsor, European Myeloma Network.</p><p> </p><p> </p><p> </p><p>Clinical trial sponsors are required to publish a summary of their trial results to the EU Clinical Trials Register within one year of their trial completing. At that point, these results will become publically available on the EU Clinical Trials Register</p><p> </p><p> </p><p> </p><p>The Department of Health, which funds the National Institute for Health Research (NIHR), is a member of the National Cancer Research Institute (NCRI). NCRI Clinical Studies Groups (CSGs) bring together clinicians, scientists, statisticians and lay representatives to coordinate development of a strategic portfolio of trials within their field. All CSGs interact with clinical research networks, funders (including NIHR) and researchers to develop studies aimed at improving outcomes for patients. The Haematological Oncology CSG has a Myeloma Subgroup and its 2013-14 annual report that includes an assessment of progress in these areas is attached and available on the NCRI website at:</p><p> </p><p><a href="http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf" target="_blank">http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf</a>.</p><p> </p><p> </p><p> </p><p>We cannot comment on commercial considerations. When the results are known, the commercial potential of these trial’s products will be a matter for the respective trial sponsors.</p><p> </p> answering member printed Lord Prior of Brampton grouped question UIN HL995 HL997 question first answered 14/07/2015 15:34:29 answering member 127 label Biography information for Lord Prior of Brampton attachment 1 file name NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf title 2013-14 Annual Report
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

386886

	registered interest
	date	01/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Amyloidosis and Multiple Myeloma
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government whether they will place in the Library of the House any publications resulting from the phase 3 clinical trials approved for the potential treatment of systemic amyloidosis or multiple myeloma; and what is the National Institute of Health Research’s assessment of progress in these areas.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL995
	answer	answer is ministerial correction date of answer 14/07/2015 answer text <p>There are four trials for systemic amyloidosis that are designated as ‘ongoing’ in the United Kingdom. These are being conducted by two commercial sponsors, Millennium Pharmaceuticals Inc and A.T. Development Switzerland Sarl (two studies), and one non-commercial sponsor, European Myeloma Network.</p><p> </p><p> </p><p> </p><p>Clinical trial sponsors are required to publish a summary of their trial results to the EU Clinical Trials Register within one year of their trial completing. At that point, these results will become publically available on the EU Clinical Trials Register</p><p> </p><p> </p><p> </p><p>The Department of Health, which funds the National Institute for Health Research (NIHR), is a member of the National Cancer Research Institute (NCRI). NCRI Clinical Studies Groups (CSGs) bring together clinicians, scientists, statisticians and lay representatives to coordinate development of a strategic portfolio of trials within their field. All CSGs interact with clinical research networks, funders (including NIHR) and researchers to develop studies aimed at improving outcomes for patients. The Haematological Oncology CSG has a Myeloma Subgroup and its 2013-14 annual report that includes an assessment of progress in these areas is attached and available on the NCRI website at:</p><p> </p><p><a href="http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf" target="_blank">http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf</a>.</p><p> </p><p> </p><p> </p><p>We cannot comment on commercial considerations. When the results are known, the commercial potential of these trial’s products will be a matter for the respective trial sponsors.</p><p> </p> answering member printed Lord Prior of Brampton grouped question UIN HL996 HL997 question first answered 14/07/2015 15:34:29 answering member 127 label Biography information for Lord Prior of Brampton attachment 1 file name NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf title 2013-14 Annual Report
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

386885

	registered interest
	date	01/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Multiple Myeloma
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government when they expect the National Institute of Health Research Technology Assessment programme to publish initial findings from its assessment of the benefits of antibiotic prophylaxis and its effect on healthcare associated infections in myeloma patients.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL994
	answer	answer is ministerial correction date of answer 09/07/2015 answer text <p>This trial is led by the University of Birmingham. The project is recruiting ahead of schedule and expects to reach its target of 800 in the near future. The target was to do so by the end of November 2015. Publication of initial findings is expected in 2017.</p><p> </p> answering member printed Lord Prior of Brampton question first answered 09/07/2015 13:00:57 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

386884

	registered interest
	date	01/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Amyloidosis
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what progress has been made on setting up a study to image amyloid deposition in systemic amyloidosis using hybrid positron emission tomography-magnetic resonance imaging; where the study is located; how many patients have been recruited; when the study is expected to complete its initial work; and where the results will be published.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL993
	answer	answer is ministerial correction date of answer 14/07/2015 answer text <p>This is a single centre study at University College London Hospital. It has now been set up and one patient has been recruited and scanned. The current planned date for end of recruitment is 1 October 2016. It is anticipated that the data will be analysed and submitted for publication in a peer reviewed journal within a year of the end of recruitment.</p><p> </p> answering member printed Lord Prior of Brampton question first answered 14/07/2015 15:36:20 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

58574

	registered interest
	date	05/06/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Mental Health Services
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether personality disorder services remain a priority commitment for the National Health Service; and if so, what guidance is provided to NHS England to ensure that quality services continue to be commissioned.
	tabling member printed	Lord Alderdice
	uin	HL99
	answer	answer is ministerial correction date of answer 19/06/2014 answer text Personality disorder services remain a priority commitment for the National Health Service. In 2011 the Government published No health, without mental health, a cross Government mental health outcomes strategy for people of all ages which remains the Government's vision for improving services for people with mental health problems; this specifically includes people with personality disorders. The Mandate to NHS England makes clear that by March 2015, we expect NHS England to make measurable progress towards achieving true parity of esteem between mental and physical health and that everyone who needs it should have timely access to evidence-based services. answering member printed Earl Howe question first answered 19/06/2014 11:56:04 answering member 2000 label Biography information for Earl Howe
	tabling member	3478 label Biography information for Lord Alderdice

947606

	registered interest
	date	24/07/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	General Practitioners: Insurance
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assessment they have made of the difference in the insurance premium paid by GPs in England and Scotland; and what assessment they have made of the reasons for such difference.
	tabling member printed	Lord Mawson
	uin	HL9874
	answer	answer is ministerial correction date of answer 26/07/2018 answer text <p>General practitioners (GPs) are required to have adequate and appropriate indemnity or insurance arrangements to cover clinical negligence liabilities.</p><p>We do not have data showing the difference on insurance premiums, which are a very small proportion of the market in England. The Department is aware that there is a difference in the cost of clinical negligence indemnity subscriptions paid by GPs in England and Scotland. No assessment has been made for the reasons for such difference.</p><p>Health is a devolved matter and it is for the devolved administrations to make their own decisions about health policies in their own territories.</p> answering member printed Lord O'Shaughnessy question first answered 26/07/2018 12:45:16 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	3830 label Biography information for Lord Mawson

947567

	registered interest
	date	24/07/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	PrescQIPP
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assurances they have received from PresQIPP that when providing guidance to Clinical Commissioning Groups on commissioning decisions it has taken the views of patient stakeholders into account.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL9849
	answer	answer is ministerial correction date of answer 26/07/2018 answer text <p>We have not made any assessment on the accuracy and advice provided by PrescQIPP. Nor have we made any assessment on whether the advice provided by PrescQIPP to clinical commissioning groups (CCGs) is consistent with national guidelines on the prescription of liothyronine to National Health Service patients. We can confirm that we have not received any assurances from PrescQIPP on whether or not it has taken patient stakeholder views into account as it is the responsibility of CCGs to seek any such assurances.</p><p>PrescQIPP is an independent social enterprise and it is for CCGs to decide whether and how they take that guidance into account when making decisions. However, NHS England expects CCGs to have due regard to the guidance <em>Items which should not routinely be prescribed in primary care: Guidance for CCGs,</em> published in November 2017 by NHS England and NHS Clinical Commissioners when considering the prescribing of liothyronine. A copy of the guidance is attached.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL9847 HL9848 question first answered 26/07/2018 12:46:36 answering member 4545 label Biography information for Lord O'Shaughnessy attachment 1 file name items-which-should-not-be-routinely-precscribed-in-pc-ccg-guidance.pdf title Items which should not routinely be prescribed
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath